Canadian Cancer Trials Group Bulletins

General


Highly Cited Cancer Papers, 2008-2010

In its most recent issue, the journal Nature Medicine has published lists of the most highly-cited primary research papers on cancer published between 2008 and 2010. Canadian Cancer Trials Group publications are included in each of the three years!! You can find this listing online at http://www.nature.com/nm/journal/v17/n3/full/nm0311-280.html#/t1.

#6 of Most Highly Cited Papers in 2008

Karapetis, C.S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765.

This publication is related to Canadian Cancer Trials Group CO.17 -- A Phase III Randomized Study of Cetuximab (Erbitux TM, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR) - Positive Colorectal Carcinoma.


#19 of Most Highly Cited Papers in 2009

Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466.

This publication is related to Canadian Cancer Trials Group CE.3 (EORTC 26981) -- A Randomized Phase III Study of Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme


#19 of Most Highly Cited Papers in 2010

Albain, K.S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55-65.

This publication is related to Canadian Cancer Trials Group MA.9 (SWOG 8814) -- Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors.